Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Intra-articular Injection in Hands Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hand OA~* Age over 40~* Visual analogic scale (VAS) for pain at rest between 3-8cm~* Signed informed consent term~Exclusion Criteria:~* Change in the use of oral corticosteroid or nonsteroidal antiinflammatory (NSAID) in the last 30 days~* Change in drugs for OA in the last two months~* IAI in this joints in the last three months~* Any change in treatment for OA in the hands in the last two months~* Suspicion of local and or systemic infection, and pregnancy~* Hands X-ray suggesting arthropathy of the interphalanges of other etiology~* Serious coagulation disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IAI triamcinolone hexacetonide (Type: EXPERIMENTAL): Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day).
- IAI lidocaine (Type: PLACEBO_COMPARATOR): Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.

Based on this trial design, predict the completion outcome and termination type (if applicable).